89zr-dfosq-olaratumab
mAbexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2024 (NCT06537596)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
PDGFRA inhibitor
Chemistry & pharmacology
- Imaging
- 89-zirconium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06537596 | Phase 1 | Aug 31, 2024 | Telix |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Telix | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1